Curriculum Vitae

Hector D. Ceccoli, MD, FACC
1783 Troup Hwy, Tyler, Texas 75701
Office (903)-595-2283 Fax (903)-597-2238

Practice

2005-Present	Cardiovascular Associates of East Texas, P.A.
2009-Present	Tyler Cardiac and Endovascular Center 1769 Troup Hwy, Tyler, Texas

Affiliation

2005 – Present	CAET - Research - 1761 Troup Hwy, Tyler, Texas
1/1/13-4/26/13	TAD Clinical Research - 1741 Troup Hwy, Tyler, Texas

Education

Post-Graduate Training/Medical Education

1996-1999	Cardiology Fellowship University of Illinois at Chicago
1992-1996	Internal Medicine Residency University of Illinois at Chicago
1983-1990	Medical School Universidad Nacional de Rosario Rosario, Santa Fe, Argentina

Board Certification

Nuclear Cardiology Board Certification

Licensure

Texas Medical License

Hospital Appointments

CHRISTUS Trinity Mother Frances, Tyler, Texas

CHRISTUS Trinity Mother Frances, Jacksonville, Texas

CHRISTUS Trinity Mother Frances, Winnsboro, Texas

UT Health East Texas (ETMC), Tyler, Texas

Baylor Scott & White Texas Spine and Joint Hospital, Tyler, Texas

Research

Co-Investigator - FORXIGA-HF - Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. (D1699C00001)

Co-Investigator - PROVE-HF - A 52 Week, open label evaluation on the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction.

Co-Investigator - CHAMP-HF – Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction.

Co-Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

Co-Investigator - ANALYZE ST - Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Co-Investigator – LSS 4 SITE **-** The Longitudinal Surveillance Study of the 4-SITE Lead/Header System

Co-Investigator – INGEVITY **-** Active Fixation and Passive Fixation Pace/Sense Lead Clinical Study

Co-Investigator – ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Co-Investigator – SUMMIT - HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Co-Investigator – DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator – ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator – AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI).

Co-Investigator – EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator – EUCLID **-** A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD).

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Co-Investigator – RATE Registry – Registry of AT/AF Episodes in the CRM Device Population

Primary Investigator – OPTIMUM Registry - A prospective, outcome-oriented registry of patients implanted with SJM Optim™ leads. This registry evaluated the chronic performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with Optim™ insulation material.

Co-Investigator – RE-LY Study - **R**andomized **E**valuation of **L**ong term anticoagulant therap**y** (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Investigator – TRENDS - A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.

Co-Investigator – OMNI Study - Post-market observational study conducted in the United States. The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe ICD therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants.

Co-Investigator - ULTRA study- Ventricular Automatic Capture assessment Study.

Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Co-Investigator – ST Monitoring to Detect ACS Events in ICD Patients (Analyze ST)

Primary Investigator – TRACER – " A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome."

Primary Investigator – St. Jude Medical Product Longevity and Perforamce (SCORE) Registry

Co-Investigator - Taxus Libertē "A prospective, multi-center study designed to observe clinical outcomes in patient receiving the TAXUS Libertē-Paclitaxel-Eluting Coronary Stent and prasugrel as part of a dual antiplatelet therapy drug regimen"

Co-Investigator - RESOLUTE US: "A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of *De Novo* Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm."

Co-Investigator - TAO: "A randomized, double-blind, triple-dummy trial to compare the efficacy of otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy"

Co-Investigator - VISTA-16 Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndromes

Co-Investigator - ENDEAVOR SVS Registry: "A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single *De novo* Lesions in Small Diameter Native Coronary Arteries"

Co-Investigator - Quick FLEX Model 1258T Left Heart Pacing Lead Post Approval Study

Co-Investigator - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial – IMPROVE IT.